Evidence map›Paper›PMID 40337266›Full record

ArticlePrecision radiation oncology2023

Extensive-stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?

Yuanhu Yao, Nan Yao, Zhaohui Qin, Ji Ma, Jiaying Lu, Li Cui, Wanxi Qu, Shiwang Yuan, Shaodong Tong, Na Li and 1 more

Abstract read
In one paragraph

Article in Precision radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Prophylactic cranial irradiation in the era of immunotherapy in extensive-stage small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuanhu YaoDepartment of Radiation Oncology The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi Jiangsu China.ORCID https://orcid.org/0000-0001-7332-600X
Nan YaoGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Zhaohui QinResearch Center for Medical and Health Emergency Rescue Xuzhou Medical University Xuzhou Jiangsu China.
Ji MaGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Jiaying LuGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Li CuiGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Wanxi QuGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Shiwang YuanGraduate School of Xuzhou Medical University Xuzhou Jiangsu China.
Shaodong TongDepartment of Radiation Oncology The Third People's Hospital of Xuzhou Xuzhou Jiangsu China.
Na LiDepartment of Radiation Oncology Xuzhou Central Hospital Xuzhou Jiangsu China.
Hao LiDepartment of Oncology Xuzhou Central Hospital Xuzhou Jiangsu China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The role of prophylactic cranial irradiation (PCI) in treating extensive-stage small-cell lung cancer (ES-SCLC) has been controversial. This study aimed to comprehensively analyze the efficacy of PCI for the treatment of ES-SCLC under active brain magnetic resonance imaging (MRI) surveillance. Methods: Patients with ES-SCLC with no brain metastases (BM) confirmed by MRI at the time of diagnosis who responded well to first-line chemoimmunotherapy at three general hospitals were retrospectively included. Overall survival (OS), progression-free survival (PFS), and cumulative incidence of BM were compared between patients who underwent PCI and those who did not. Results: In total, 66 consecutive patients treated between March 2019 and December 2021 were included in our dataset. Seventeen patients underwent PCI (PCI group) and 49 patients did not (non-PCI group). In comparison with the non-PCI group, PCI did not provide OS (median OS: 18.53 Conclusion: Compared to active MRI surveillance, first-line chemoimmunotherapy followed by PCI did not improve the prognosis of patients with ES-SCLC. Further studies are warranted to evaluate the therapeutic effects of PCI following chemoimmunotherapy.

Indexed as

brain metastasesextensive‐stage small cell lung cancerimmunotherapymagnetic resonance imagingprophylactic cranial irradiation

Identifiers

PMID40337266
PMCPMC11935183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.